mnpr20240610

0001437749-24-019881.txt : 20240611 0001437749-24-019881.hdr.sgml : 20240611 20240611073032 ACCESSION NUMBER: 0001437749-24-019881 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241034609 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240610_8k.htm FORM 8-K mnpr20240610_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39070		32-0463781
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1000 Skokie Blvd., Suite 350, Wilmette, IL		60091
(Address of principal executive offices)		(Zip Code)

(847) 388-0349

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		MNPR		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

On June 11, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing an amendment and expansion to their existing collaboration with NorthStar Medical Radioisotopes, LLC.

The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Description
99.1		Press Release Dated June 11, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Monopar Therapeutics Inc.

Date: June 11, 2024	By:	/s/ Kim R. Tsuchimoto
	Name:	Kim R. Tsuchimoto
	Title:	Chief Financial Officer and Director

EX-99.1 2 ex_686102.htm EXHIBIT 99.1 ex_686102.htm

Exhibit 99.1

Monopar and NorthStar Amend & Extend Collaboration

Highlights:

●

Builds on Companies’ respective core strengths

●

Aligns intellectual property rights

●

Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs

WILMETTE, IL and Beloit, WI, June 11, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator in development and commercial production of medical radioisotopes, today announced an amendment and expansion to their existing collaboration. Under terms of the revised collaboration, the Companies entered into a long-term, non-exclusive master supply agreement for NorthStar to provide Monopar with the powerful therapeutic radioisotope actinium-225 (Ac-225). The amendment builds on NorthStar’s significant investment in Ac-225 manufacturing and Monopar’s promising preclinical therapeutic results with Ac-225 in its lead MNPR-101 radiopharma program.

The amendment also clarifies certain economic terms and those related to jointly developed intellectual property rights for Monopar’s MNPR-101 for radiopharmaceutical use. Monopar has acquired those rights from NorthStar, together with certain broad, jointly developed intellectual property pertaining to MNPR-101, giving Monopar full ownership and title to its lead MNPR-101 radiopharmaceutical platform. Both companies will share ownership of the filed patent application on the use of PCTA as a linker with Ac-225, which has shown superior binding and yield with Ac-225 over the current industry-leading linker, DOTA.

“We are excited about the evolution of our collaboration, the promising potential of the MNPR-101 radiopharma platform, and the long-term access to a high-quality source of Ac-225 that can support our current development programs and potential future commercial products,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

“Using our proprietary electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) Ac-225. We’re delighted to continue and extend our collaboration with Monopar and support development of its exciting MNPR-101 radiopharma platform focused on therapeutic agents to treat aggressive cancers,” said Frank Scholz, PhD, NorthStar’s Chief Executive Officer.

About Monopar Therapeutics Inc. (Monopar)

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

About NorthStar Medical Radioisotopes, LLC (NorthStar)

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that NorthStar will provide actinium-225 for Monopar’s development and potential future commercial programs; the promising potential of Monopar’s MNPR-101 radiopharma platform, and the long-term access to a high-quality source of Ac-225 that can support Monopar’s current development programs and potential future commercial products; that NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) Ac-225; and that NorthStar will continue to support development of Monopar’s exciting MNPR-101 radiopharma platform focused on therapeutic agents to treat aggressive cancers. The forward-looking statements involve risks and uncertainties including, but not limited to: that Monopar’s and shared intellectual property may not result in allowed patents; that if allowed, the patents may be too narrow in scope to provide protection needed to successfully develop the radiopharma program; that NorthStar may not be able to supply Ac-225 at quantities needed, if at all; that NorthStar may not be the first commercial-scale producer of n.c.a. Ac-225; that Monopar may expend available funds sooner than anticipated or require additional funding due to change in circumstances or unanticipated events; that future preclinical or clinical data will not be as promising as the data to date; not successfully enrolling the MNPR-101-Zr Phase 1 clinical trial if at all; that MNPR-101-Zr and/or MNPR-101 conjugated to a therapeutic radioisotope may cause unexpected serious adverse effects or fail to image or be effective against the cancer tumors in humans; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s and/or NorthStar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACTS:  

For Monopar Therapeutics Inc.
Investor Relations  
Kim R. Tsuchimoto  
Chief Financial Officer  
kimtsu@monopartx.com

Follow Monopar on social media for updates:

X (formerly Twitter): @MonoparTx LinkedIn: Monopar Therapeutics

For NorthStar Medical Radioisotopes, LLC :
Investor Relations:  
Paul Estrem  
Executive Vice President and Chief Financial Officer
pestrem@northstarnm.com

Media/Corporate:
Alison Hess  
Vice President, Chief of Staff
ahess@northstarnm.com

EX-101.SCH 3 mnpr-20240611.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mnpr-20240611_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mnpr-20240611_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Entity, Ex Transition Period Amendment Flag Entity, Central Index Key EX-101.PRE 6 mnpr-20240611_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 monologo.jpg begin 644 monologo.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @ 0$Q ( M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! M 0$! 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** , MWQ#KEIX:\/7NL:BVVWM(C(P'5CV4>Y. /K7*?"GQ_-XUT:ZCU=(X-8LI?W\* M=#&_,;#\/E/NI]:X7XU>*?[8\00^%[-]UGII6XOB#Q).1F./_@(^8^Y7TKC/ M#OB*7P?XKL]?BW&&(^3?(O\ RTMV/S?4J<,/H:ZH8=RI.9:CI<^JJ*9!/%0119VN!)111 M2 **** "BBB@ HHHH ***IZEJ^GZ/ LVJ7<5K&[;5:5L GKBFDV[("Y16!_P MG7A?_H.V7_?T5POYJ],#J?TIV>X%NBJ6D:Q8ZYIZWNES>=;LQ4-M*\CKP>:NT--.S * M***0!535+B6VTNXDM6A6X$;>3Y[[$+X^7)],U;KYE^./C#_A)/%XT2TDW:;H MY*N ?EEN#]X^^T+WED>:^T&YNKB5 MI9I3J#;I9&.2?N5-+\)_%T3&.>30D)'*O?,./H4KS+0(DC\5:,R(%/\ :%OR M!C_EH*[+XY(K_%R^WC=BTM\9[?*:J.8S]ESK9>AZD\HJPQL<'SJ[5[].O^1[ MA\*],UG0?"2Z+K]S97#6;D6K6MP9=L)Y5&) /R\@>V/2NVKXU\%^)I/!'BZS MUN -Y$;>7>1)_P M(6^]QZC[P^E?8MM:AI7,^GP1W)7^\JJNX?D37M=< M-%H-^WQBN]4ELV.G2V?E><<;6.U01Z]C7;AY*+;?8X8NQR'Q \2OXQL1#HK' M^S[&V6[NW_VVP%3ZC/YY]*Z.?Q7<^'O ?A>STJ&.;4M1MH8H!+]U?E49/XD5 M=UKP1;:9X$U;3O#-F[S7C!RF[+,01P">P&<"L[6O"FKR^%_"UYI]MOU+18HM M]JS %L!'M#CL=MN 4FG4@1+A22<=3EL5'>V.O>-O%& MCRWNC2:38:=*)I&F<%G8$' Q] *OZ%H>I6OQ7US5+BU=+*XB BF)&'/R?X&I M]Q*[2O;]1:"^%?%^J2:WJFA^*8X1=Z?$9_.MQA708SQ^((K-LO$_C3Q)IUYK M>AKIUMI]N["*"=2SRA1D\_\ ZJO6OA[4'^*>M7L]L\=A=V+0I<9&"3L&.OL? MRK*T:+Q5X2T&^\/Q^'Y+_<[_ &:ZBD&PAAC)_G3M!ZQM?3_@AH7;_P"(MW+\ M-(_$&FPQ17?V@02QR*656[X^HP?QJ#5?%7C;0;"UU[4K;3SILS+OM(P=\:MR M,MZ_GSVK(\1>')_#'P92SO6!N9+U9I0IR%)XQGZ 5>UQ/%WBKP_9>'WT'[." M8S+>^:#&P4<,/3UQUJU&GNDK7?W#LCK/$.L:XT5BWAU;."UN8Q))J%ZX"1 C M(&,]AS_ )Z4GA7P_JUO\1+K5)]"CTJQELF2**';M3.W M"G'\7!S6:C3]GTV%I8;H'BWQQXE\_P#LRTT_R;>Y*23R KD?W0,]0.<^XKT+ M4M'L-9MTAU:TBND1MRK(N0&QC(KEOAEHVH:+I>I1:I:O;/+>M(@8CYEVCGBN MVK&M)*=H:6["EOH>2^&O#>C77Q2\16%QIT$EK;J#%"R_*G*]/SIWBJ&;2_BC MH$'AVTA\V.V*6\+?+&N=XR<=ADG\*Z#PYHFHV?Q/\0:E=CSWQR9GY& / M3@U9\2Z'J5[\3O#VHVMJ\EG:K^^E!&$Y/7\ZPI_",VA^*]3N)_"Z^(+"];S8 M&4C="Q))!S]?T%**IO72]OU%H:UCX_O;SP5K=T\5NFK:1\K[/FB?G 8<].#W MJ;PGKGC/7?L.H7=G8Q:5)&2^T_O), \@9XR156+P[J+_ _UN,:!9Z=>7J!8 MK6S'S, >-QSC/)K?T'3-1MOAM;Z<,VFHK9M&NX\QN0< MSNX3#=Q7# QN?NG)(SC\*V4*;DEIO^%AV1T.I>*?&'A>]L+SQ%#82:=>3"-H MK<'=#GG&3WQ]0<&K_B'Q?J)\6+X=T"6RM9$B$MQ>7I^5 1D #UP1^=9'B"V\ M5^-9M.TJ[T/^SH+>X$MS/>I?%'A.X@\';7Q=X9T:]\.0Z!]H,LC^3>>:!&-PQN/MQFE*,)72M?3 M_@BLAS>(/$?BCX4WM_&;)2//2[#(1F$)_#S][DU:^'S^((/!JS7)L7TA+.5H M(]I,A8$XW=B.M6?!GAC48?ACJ&BZC UI^>M.3CRRC&VXWV*^G^.I-,^%<>LO9VPNI;AH(88 M(_+C+9.#@>P)]ZLKK'CW27LKO5+*TU&SN6 EALXV\R$'_/O69#X'U:]^$D.E MO ;?4K:[:YCBD(&[D\9Z<@UJ+JWCG5#86-GHYT']+NK#2UBA$AN;\'$A(!P.PZX_ UU'AF[UJZT]_\ A(;> MVCF1L)-:R!HYU_O 9.*Y[Q5;WEQJ[1ZGX2AUS3MF(9X"!,AP,@GJ.<]*7X:: M#JNBVVH'48GM+6XFW6MG))O:)>>I^F![XK*2C[*ZL)VL6/BCXS'@GP3<7D#* M=0N3]GL4/>5A]['HHRQ^GO7R8H(!+NSNQ+.[')9BXDC2-DMW4+A1@=0?6I6'DJ+IWU?_ -ZF'? M@;HWAGQ'9:UI^L:J;FS1"K C!4C;R"*,/AYTI7OH/-LVPN/HJ*@U);/3 MY]3TVBBBNT^6"BBB@ HHHH **** ,OQ!X?LO$VE_8-2\SR=X?]VVTY'O6E%& ML,*1)]U%"C/H*=13N[6 ****0!1110 4444 %%%% !1110 5D>(?#.G^)H;> I+4_-VV\GFIY;[>?>M>BFFXNZ ****0!1110 4444 %%%% !1110!_]D! end XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Jun. 11, 2024
Document Information [Line Items]
Entity, Registrant Name	MONOPAR THERAPEUTICS INC.
Document, Type	8-K
Document, Period End Date	Jun. 11, 2024
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-39070
Entity, Tax Identification Number	32-0463781
Entity, Address, Address Line One	1000 Skokie Blvd.
Entity, Address, Address Line Two	Suite 350
Entity, Address, City or Town	Wilmette
Entity, Address, State or Province	IL
Entity, Address, Postal Zip Code	60091
City Area Code	847
Local Phone Number	388-0349
Title of 12(b) Security	Common Stock
Trading Symbol	MNPR
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	true
Entity, Ex Transition Period	true
Amendment Flag	false
Entity, Central Index Key	0001645469

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mnpr.com/20240611/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mnpr-20240611.xsd mnpr-20240611_def.xml mnpr-20240611_lab.xml mnpr-20240611_pre.xml mnpr20240610_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mnpr20240610_8k.htm": { "nsprefix": "mnpr", "nsuri": "http://www.mnpr.com/20240611", "dts": { "schema": { "local": [ "mnpr-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "mnpr-20240611_def.xml" ] }, "labelLink": { "local": [ "mnpr-20240611_lab.xml" ] }, "presentationLink": { "local": [ "mnpr-20240611_pre.xml" ] }, "inline": { "local": [ "mnpr20240610_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 28, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.mnpr.com/20240611/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "mnpr20240610_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "mnpr20240610_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mnpr.com/20240611/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001437749-24-019881-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-019881-xbrl.zip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

BA2I-=,^7&(F7)7GZ4+(::$4'%\I.)P6\T1'2

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end XML 19 mnpr20240610_8k_htm.xml IDEA: XBRL DOCUMENT 0001645469 2024-06-11 2024-06-11 false 0001645469 8-K 2024-06-11 MONOPAR THERAPEUTICS INC. DE 001-39070 32-0463781 1000 Skokie Blvd. Suite 350 Wilmette IL 60091 847 388-0349 Common Stock MNPR NASDAQ false false false false true true